Advertisement
ATEC or IRTC or SIBN
Which Stock Would AI Choose? Alphatec Holdings (ATEC) vs. iRhythm Holdings (IRTC) vs. SI-BONE (SIBN) Stock Comparison
Key Takeaways
- ATEC reported Q1 2026 revenue growth of 14% year-over-year to $192 million, with surgical volumes up 17%, but shares dropped sharply post-earnings due to a revenue miss versus expectations.
- IRTC delivered Q1 revenue of $199 million, up 26% year-over-year, beating estimates and raising full-year guidance, supporting positive momentum in cardiac monitoring.
- SIBN achieved record FY2025 revenue of $201 million, up 20%, with positive adjusted EBITDA and guidance for 14-16% growth in 2026, reflecting steady sacroiliac joint fusion adoption.
- All three medtech firms focus on specialized surgical and monitoring solutions, with recent earnings highlighting volume-driven growth amid sector volatility.
- IRTC shows the strongest recent revenue acceleration and market cap stability at ~$3.8B, while ATEC (~$1.1B) faces higher short-term pressure.
- YTD returns vary: IRTC +34%, SIBN +31%, contrasting ATEC's declines amid post-earnings reaction.
Introduction
This comparison examines ATEC, IRTC, and SIBN, three medtech companies specializing in spinal surgery, cardiac monitoring, and orthopedic implants. These stocks appeal to growth-oriented traders tracking healthcare innovation, particularly amid rising procedural volumes and AI-enhanced diagnostics. Recent quarterly results reveal contrasts in revenue execution and market reactions, offering insights into relative performance, sector tailwinds like minimally invasive procedures, and risks from earnings volatility. Investors monitoring stock comparisons for relative strength in the medical devices space will find value in their shared focus on procedure-driven revenue amid broader market positioning.
ATEC Overview and Recent Performance
Alphatec Holdings, Inc. (ATEC) develops technologies for spinal disorder treatments, including implants, biologics, and the Alpha InformatiX platform with imaging and neuromonitoring systems. In recent market activity, the stock experienced significant pressure following Q1 2026 results, with shares dropping over 30% in a session amid high volume. Total revenue reached $192 million, up 14% year-over-year, driven by 17% surgical revenue growth and 21% case volume increase, alongside 23% net new surgeon adoption. Adjusted EBITDA rose to $21 million (11% margin), but a miss on total revenue expectations and EOS imaging softness tempered sentiment. The company refinanced debt, cutting interest by $6 million annually and extending maturities to 2031, bolstering balance sheet flexibility. Broader YTD declines reflect earnings reaction, contrasting prior growth momentum.
IRTC Overview and Recent Performance
iRhythm Holdings, Inc. (IRTC), formerly iRhythm Technologies, provides ambulatory cardiac monitoring via the Zio patch system, capturing up to 14-day ECG data with AI analysis. Recent weeks saw shares react positively to Q1 2026 earnings, with revenue of $199 million surging 26% year-over-year on sustained volume demand across channels, beating consensus by 3%. Adjusted loss narrowed to $0.35 per share, with EBITDA at $14 million (7% margin), prompting raised FY2026 guidance to $875-885 million. Gross margins expanded 210 basis points to 71%, fueled by core Zio XT/AT adoption and primary care expansion. YTD gains of ~34% outpace the S&P 500, supported by free cash flow progress and AI integrations, though longer-term returns lag amid prior volatility.
SIBN Overview and Recent Performance
SI-BONE, Inc. (SIBN) specializes in implants for sacroiliac joint fusion and pelvic fixation, including the iFuse system for biomechanical stabilization. Recent performance reflects steady execution, with FY2025 revenue hitting a record $201 million, up 20% year-over-year, and Q4 at $56 million (15% growth). The company achieved positive adjusted EBITDA and free cash flow in Q4, with 18% physician adoption growth to 1,640 users. Guidance for 2026 projects 14-16% worldwide revenue expansion to $228-233 million, aided by partnerships like Smith & Nephew for iFuse TORQ distribution. Shares have shown resilience with ~31% YTD gains, driven by procedural volume and margin improvements, positioning it favorably in orthopedics.
Trending AI Robots
Tickeron’s Trending AI Robots page features a curated selection of 25 top-performing AI trading bots from over 351 available, designed to adapt to current market conditions across stocks, ETFs, and crypto. These bots employ diverse strategies like AI/ML signal generation, risk-managed virtual agents, and copy-trading brokerage models, targeting sectors such as semiconductors, industrials, small caps, and volatility plays. Performance highlights include annualized returns from +23% to +169%, win rates of 51-88%, and trade durations from 1 day to 48 days, trading 3 to 18 tickers per bot—e.g., a space imaging bot with +127% return (56% win rate, 3 tickers) or semiconductors at +95% (6 tickers). This dynamic leaderboard showcases bots excelling in today’s environment, varying by timeframe, risk, and assets. Traders can explore these for potential edge in volatile markets; visit the page to review live stats and suitability.
Head-to-Head Comparison
ATEC, IRTC, and SIBN operate in medtech niches—spinal implants, cardiac diagnostics, and SI joint fusion—with procedure volumes as core growth drivers. IRTC leads revenue scale (~$750M FY25) and acceleration (26% Q1 growth), benefiting from AI-enhanced monitoring and EHR integration, but carries higher valuation sensitivity in diagnostics. ATEC (764M FY25 revenue, 25% growth) emphasizes surgeon adoption in competitive spine, with robotics catalysts yet elevated risks from debt and earnings misses. SIBN (201M FY25, 20% growth) offers niche stability via patented iFuse, recent profitability inflection, and distribution deals, though smaller scale limits momentum. Sentiment favors IRTC’s beats; all face reimbursement and competition headwinds, trading at discounts to historical medtech multiples amid YTD volatility contrasts.
Tickeron AI Verdict
Tickeron’s AI currently favors IRTC based on superior recent trend consistency, with 26% revenue growth, guidance raises, and margin expansion signaling stronger near-term catalysts relative to peers. SIBN follows for profitability progress, while ATEC lags on post-earnings volatility despite volume gains. This probabilistic edge reflects observable momentum, not guarantees.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ATEC’s FA Score shows that 0 FA rating(s) are green whileIRTC’s FA Score has 0 green FA rating(s), and SIBN’s FA Score reflects 0 green FA rating(s).
- ATEC’s FA Score: 0 green, 5 red.
- IRTC’s FA Score: 0 green, 5 red.
- SIBN’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ATEC’s TA Score shows that 4 TA indicator(s) are bullish while IRTC’s TA Score has 3 bullish TA indicator(s), and SIBN’s TA Score reflects 6 bullish TA indicator(s).
- ATEC’s TA Score: 4 bullish, 4 bearish.
- IRTC’s TA Score: 3 bullish, 6 bearish.
- SIBN’s TA Score: 6 bullish, 3 bearish.
Price Growth
ATEC (@Medical/Nursing Services) experienced а +1.93% price change this week, while IRTC (@Medical/Nursing Services) price change was -5.52% , and SIBN (@Medical/Nursing Services) price fluctuated +15.48% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -1.53%. For the same industry, the average monthly price growth was -5.85%, and the average quarterly price growth was -5.88%.
Reported Earning Dates
ATEC is expected to report earnings on Jul 30, 2026.
IRTC is expected to report earnings on Jul 30, 2026.
SIBN is expected to report earnings on Aug 10, 2026.
Industries' Descriptions
@Medical/Nursing Services (-1.53% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
| ATEC | IRTC | SIBN | |
| Capitalization | 1.18B | 3.75B | 628M |
| EBITDA | 6.36M | 12.6M | -10.51M |
| Gain YTD | -63.569 | -35.753 | -28.144 |
| P/E Ratio | N/A | N/A | N/A |
| Revenue | 787M | 788M | 201M |
| Total Cash | 140M | 550M | 148M |
| Total Debt | 603M | 729M | 36.7M |
ATEC | IRTC | SIBN | ||
|---|---|---|---|---|
OUTLOOK RATING 1..100 | 58 | 54 | 14 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 99 Overvalued | 50 Fair valued | 37 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 80 | 100 | |
SMR RATING 1..100 | 100 | 96 | 93 | |
PRICE GROWTH RATING 1..100 | 95 | 83 | 61 | |
P/E GROWTH RATING 1..100 | 100 | 100 | 100 | |
SEASONALITY SCORE 1..100 | 90 | n/a | 31 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
SIBN's Valuation (37) in the Medical Specialties industry is in the same range as IRTC (50) and is somewhat better than the same rating for ATEC (99). This means that SIBN's stock grew similarly to IRTC’s and somewhat faster than ATEC’s over the last 12 months.
IRTC's Profit vs Risk Rating (80) in the Medical Specialties industry is in the same range as SIBN (100) and is in the same range as ATEC (100). This means that IRTC's stock grew similarly to SIBN’s and similarly to ATEC’s over the last 12 months.
SIBN's SMR Rating (93) in the Medical Specialties industry is in the same range as IRTC (96) and is in the same range as ATEC (100). This means that SIBN's stock grew similarly to IRTC’s and similarly to ATEC’s over the last 12 months.
SIBN's Price Growth Rating (61) in the Medical Specialties industry is in the same range as IRTC (83) and is somewhat better than the same rating for ATEC (95). This means that SIBN's stock grew similarly to IRTC’s and somewhat faster than ATEC’s over the last 12 months.
SIBN's P/E Growth Rating (100) in the Medical Specialties industry is in the same range as IRTC (100) and is in the same range as ATEC (100). This means that SIBN's stock grew similarly to IRTC’s and similarly to ATEC’s over the last 12 months.
| ATEC | IRTC | SIBN | |
|---|---|---|---|
| RSI ODDS (%) | 2 days ago 86% | N/A | N/A |
| Stochastic ODDS (%) | 2 days ago 81% | 2 days ago 78% | 2 days ago 87% |
| Momentum ODDS (%) | 2 days ago 85% | 2 days ago 71% | 2 days ago 71% |
| MACD ODDS (%) | 2 days ago 86% | 2 days ago 75% | 2 days ago 71% |
| TrendWeek ODDS (%) | 2 days ago 80% | 2 days ago 78% | 2 days ago 74% |
| TrendMonth ODDS (%) | 2 days ago 86% | 2 days ago 77% | 2 days ago 82% |
| Advances ODDS (%) | 2 days ago 83% | 20 days ago 78% | 3 days ago 74% |
| Declines ODDS (%) | 6 days ago 83% | 2 days ago 80% | 6 days ago 80% |
| BollingerBands ODDS (%) | 2 days ago 72% | 2 days ago 80% | 2 days ago 73% |
| Aroon ODDS (%) | 2 days ago 86% | 2 days ago 80% | 6 days ago 81% |
Advertisement
ATEC and
Correlation & Price change
A.I.dvisor indicates that over the last year, ATEC has been loosely correlated with SIBN. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if ATEC jumps, then SIBN could also see price increases.
| Ticker / NAME | Correlation To ATEC | 1D Price Change % | ||
|---|---|---|---|---|
| ATEC | 100% | +1.25% | ||
| SIBN - ATEC | 44% Loosely correlated | -2.95% | ||
| TMDX - ATEC | 43% Loosely correlated | +1.87% | ||
| IRTC - ATEC | 42% Loosely correlated | -0.14% | ||
| IRMD - ATEC | 39% Loosely correlated | -0.29% | ||
| BIO - ATEC | 37% Loosely correlated | +0.51% | ||
More | ||||
IRTC and
Correlation & Price change
A.I.dvisor indicates that over the last year, IRTC has been loosely correlated with ATEC. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if IRTC jumps, then ATEC could also see price increases.
| Ticker / NAME | Correlation To IRTC | 1D Price Change % | ||
|---|---|---|---|---|
| IRTC | 100% | -0.14% | ||
| ATEC - IRTC | 42% Loosely correlated | +1.25% | ||
| BIO - IRTC | 40% Loosely correlated | +0.51% | ||
| CNMD - IRTC | 36% Loosely correlated | -2.34% | ||
| IRMD - IRTC | 34% Loosely correlated | -0.29% | ||
| TWST - IRTC | 34% Loosely correlated | -7.20% | ||
More | ||||
SIBN and
Correlation & Price change
A.I.dvisor indicates that over the last year, SIBN has been loosely correlated with ATEC. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if SIBN jumps, then ATEC could also see price increases.
| Ticker / NAME | Correlation To SIBN | 1D Price Change % | ||
|---|---|---|---|---|
| SIBN | 100% | -2.95% | ||
| ATEC - SIBN | 44% Loosely correlated | +1.25% | ||
| EW - SIBN | 41% Loosely correlated | +0.05% | ||
| ATRC - SIBN | 40% Loosely correlated | -0.11% | ||
| QDEL - SIBN | 39% Loosely correlated | -9.39% | ||
| MDT - SIBN | 39% Loosely correlated | -1.07% | ||
More | ||||